Segment 1: Introduction and Patient Population

Moderator and AJMC co-editor-in-chief, Dr. Michael Chernew delivers a brief overview of the discussion. The discussion focuses on the use of trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta). Panelists address the patient populations for the two agents and identify which are eligible to take the targeted therapy.

Moderator and AJMC co-editor-in-chief, Dr. Michael Chernew delivers a brief overview of the discussion. The discussion focuses on the use of trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta). Panelists address the patient populations for the two agents and identify which are eligible to take the targeted therapy.

“As far as the use of pertuzumab, the current indication is for patients who either present with metastatic HER-2 positive breast cancer or those patient who have had adjuvant treatment and then have a recurrence, so it is first line treatment for HER-2 positive breast cancer,” said Dr. Swain.